Sugi Predict

Sugi Predict / Compounds / SCHEMBL340310

SCHEMBL340310

SCHEMBL340310

COc1cc(C(C)=O)c([N+](=O)[O-])cc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.56
▸ KMT2A Q03164 6/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ CTSV O60911 2/20 0.54
▸ CTSL P07711 2/20 0.54
▸ LMNA P02545 3/20 0.53
▸ MAPT P10636 3/20 0.53
▸ ABCB1 P08183 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.50
▸ GAA P10253 1/20 0.49
▸ CYP19A1 P11511 1/20 0.49
▸ HTR1A P08908 1/20 0.48
▸ ADRA1D P25100 1/20 0.48
▸ ADRA1A P35348 1/20 0.48
▸ ADRA1B P35368 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ SENP8 Q96LD8 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ SENP6 Q9GZR1 1/20 0.48
▸ HPGD P15428 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13936617 1.00 MEN1 (0.56) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL38657998 0.91 LMNA (0.64) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL159283 0.91 CTSV (0.60) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL873861 0.91 CTSV (0.60) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL15520248 0.90 CTSV (0.49) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL3420694 0.89 LMNA (0.55) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL29444157 0.89 MEN1 (0.57) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL1013111 0.89 MEN1 (0.57) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL2063806 0.89 MEN1 (0.57) MEN1KMT2AALDH1A1CTSVCTSL
SCHEMBL873729 0.89 MEN1 (0.57) MEN1KMT2AALDH1A1CTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433124-B Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2024-08-06 — — CN claimed
CN-115433124-A Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2022-12-06 — — CN claimed
CN-115433124-B Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2024-08-06 — — CN disclosed
CN-115433124-B Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2024-08-06 — — CN disclosed
CN-115433124-A Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2022-12-06 — — CN disclosed
CN-115433124-A Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline 常州佳德医药科技有限公司 2022-12-06 — — CN disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US disclosed
US-20030199513-A1 Cinnoline derivatives and use as medicine ZENECA LIMITED 2003-10-23 — — US disclosed
CN-1446214-A Cinnoline compounds ASTRAZENECA AB (SE) 2003-10-01 — — CN disclosed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP disclosed
US-6514971-B1 For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans ZENECA LIMITED (GB) 2003-02-04 — — US disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
EP-0888310-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1999-01-07 — — EP disclosed
WO-1997034876-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1997-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20030199513-A1 Cinnoline derivatives and use as medicine VEGFA, CNR1, CCR7 MEN1 1109/4885KMT2A 4370/4885ALDH1A1 761/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 MEN1 182/4885KMT2A 3184/4885ALDH1A1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.